Benjamin L. Palleiko - 11 Feb 2026 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Benjamin L. Palleiko
Issuer symbol
KALV
Transactions as of
11 Feb 2026
Net transactions value
-$52,658
Form type
4
Filing time
13 Feb 2026, 16:05:09 UTC
Previous filing
21 Jan 2026
Next filing
19 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Palleiko Benjamin L CHIEF EXECUTIVE OFFICER, Director C/O KALVISTA PHARMACEUTICALS, INC., 200 CROSSING BOULEVARD, FRAMINGHAM /s/ Benjamin L. Palleiko 13 Feb 2026 0001366244

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALV Common Stock Options Exercise +7,120 +1.7% 431,640 11 Feb 2026 Direct F1
transaction KALV Common Stock Sale $52,658 -3,354 -0.78% $15.70 428,286 12 Feb 2026 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Restricted Stock Unit Options Exercise $0 -7,120 -6.7% $0.000000 99,680 11 Feb 2026 Common Stock 7,120 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on November 11, 2025, subject to continued service through each vesting date.